Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
cbdMDYCBD -7.63%39 Cyclically Adjusted PB Ratio is 0.00 as of Jul. 18, 2026. GuruFocus rates YCBD with a GF Score™ of 39/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 759 Drug Manufacturers companies, cbdMD ranks worse than 131752.17% on this metric.
As of today (2026-07-18), cbdMD's current share price is $0.5699. cbdMD's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $353.95. cbdMD's Cyclically Adjusted PB Ratio for today is 0.00.
The historical rank and industry rank for cbdMD's Cyclically Adjusted PB Ratio or its related term are showing as below:
YCBD's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.83 * Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
cbdMD's adjusted book value per share data for the three months ended in Mar. 2026 was $0.884. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $353.95 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
cbdMD (AMEX:YCBD) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
cbdMD Cyclically Adjusted PB Ratio Related Terms
cbdMD Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for cbdMD's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YCBD vs AKAN, GELS, SNOA: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, cbdMD's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
cbdMD Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, cbdMD's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where cbdMD's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
cbdMD's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.00 mean?
cbdMD (YCBD) has a Cyclically Adjusted PB Ratio of 0.00 as of Jul. 18, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on cbdMD and its competitors. According to the industry distribution chart, cbdMD ranks #999999 out of 759 companies in the Drug Manufacturers industry.
Is cbdMD's Cyclically Adjusted PB Ratio too high?
cbdMD's current Cyclically Adjusted PB Ratio is 0.00. Based on the distribution chart, cbdMD ranks #999999 out of 759 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, cbdMD has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does cbdMD's Cyclically Adjusted PB Ratio compare to AKAN and GELS?
According to the Drug Manufacturers industry distribution chart, cbdMD ranks #999999 out of 759 companies for Cyclically Adjusted PB Ratio. This places cbdMD in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.83, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on cbdMD and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. cbdMD's current Cyclically Adjusted PB Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is cbdMD stock overvalued right now?
Based on GuruFocus' analysis, cbdMD (YCBD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $0.57 — trading 256.2% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.00. cbdMD's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For cbdMD (YCBD), the current Cyclically Adjusted PB Ratio is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is cbdMD (YCBD) Overvalued in 2026?
Based on GuruFocus' analysis, cbdMD stock appears to be overvalued.
The current stock price of $0.57 is trading 256.2% above its estimated GF Value™ of $0.16.
GuruFocus considers cbdMD to be Significantly Overvalued.
Key valuation signals for YCBD:
Cyclically Adjusted PB Ratio: 0.00
GF Value™: $0.16 vs. price of $0.57 (256.2% above fair value)
No single metric tells the full story. See the YCBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
39GF Score
Get the complete analysis for YCBD
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YCBD has been successfully added to your 
